Business
Todos Medical Releases Letter to Shareholders
Todos Medical Releases Letter to Shareholders.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders: Dear Shareholders, Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study with a view towards obtaining our own CPT code to allow for value-based, consistent reimbursement of an actionable blood test for breast cancer. I was asked by the Company’s Board of Directors to step in as CEO in early January, in large part, due to the prospective acquisition of Provista Diagnostics, which is a US-based blood testing company that has received over $50 million in investment to develop the Videssa® blood test for breast cancer. Please find here a link to the Company’s updated corporate presentation: http://investor.todosmedical.com/static-files/815190c5-2c1f-4e21-9309-dd5aab5802d1 . The Company is staying strategically focused in the area of breast cancer, while continuing to develop our Alzheimer’s diagnostic platform. Breast Cancer Over the past several weeks, as we have begun to put the infrastructure in place to re-domicile Todos from Israel to the US, I have been repeatedly asked why a company that owns TM-B2, a breast cancer blood test for the dense breast population (BI-RADS III/IV), would buy a competitor that owns Videssa, a competing breast cancer blood test for the dense breast population. Is it because you don’t believe in TM-B2? To be clear, we unequivocally believe in TM-B2. Our rationale for the business combination is as follows: Videssa has been prospectively tested in over 1,100 subjects, vs. over 400 subjects for TM-B2;As Videssa has significantly more prospective clinical validation data, it has achieved a level of clinical validation that allows it to progress to a clinical utility (reimbursement) study;Videssa has shown very strong negative predictive value (NPV) for breast cancer, but poor positive predictive value (PPV), whereas TM-B2 has shown strong NPV and PPV;We have the opportunity to dramatically accelerate the acquisition of data for TM-B2 by ‘piggybacking’ its deve...